Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus LIORESAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus LIORESAL.
DANTRIUM vs LIORESAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic reflexes at the spinal cord level by reducing excitatory neurotransmitter release.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
Oral: Initial 5 mg 3 times daily, increase by 5 mg per dose every 3 days to a maximum of 80 mg/day (20 mg 4 times daily). Intrathecal: Test dose 50-100 mcg; maintenance infusion 300-800 mcg/day.
None Documented
None Documented
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
Terminal elimination half-life: 2.5-4 hours. Clinically, accumulation occurs in renal impairment, requiring dose adjustment.
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Renal: approximately 70-80% of the dose as unchanged drug and metabolites (primarily glucuronide conjugate); minor biliary/fecal elimination (<5%).
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant